Covid-19 Patients With Hypertension and/or Kidney Diseases

NCT ID: NCT05465772

Last Updated: 2022-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-31

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. correlation between COVID-19 and Hypertension and/or kidney diseases.
2. Assess Assess the effect of COVID-19 on patients with Hypertension and/or kidney diseases.
3. Assess the effect of hypertension and/or kidney diseases on COVID-19 presentation.
4. Assess the outcome of COVID-19 in patients with hypertension and/or kidney diseases

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms¹.SARS-CoV-2 has infected humans in all age groups, of all ethnicities, both males and females while spreading through communities at an alarming rate². COVID-19 patients with hypertension, chronic kidney disease, Diabetes, malignancies, HIV, and other comorbidities could develop a life-threatening situation. From the data have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients³.

Hypertension posed an increased risk of severe morbidity (approx. 4-fold) and death (approx. 7-fold) from COVID-19 in the presence of multiple comorbidities⁴.

The patients with underlying kidney problems are vulnerable to developing COVID-19 infection.The disease also has had consequences on longitudinal management of patients with chronic kidney disease and end stage kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Hypertension Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients above 18 years old. Patients who diagnosed as COVID-19 PCR positive with hypertension and/or kidney diseases.

Exclusion Criteria

Young patients below 18 years old. Patients who refused to participate in reseach
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aya Abdelrhman Kotb Said

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aya Abdelrhman Kotb

Role: CONTACT

01069555261

Atef farouk El-karn, Professor

Role: CONTACT

01006474200

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

covid-19 patients

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Use of Angiotensin-(1-7) in COVID-19
NCT04633772 COMPLETED PHASE1/PHASE2
National Survey on Hypertension
NCT00804167 COMPLETED